Estrella Immunopharma, Inc.
ESLA
$0.9695
$0.00050.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 883.70K | 694.10K | 550.70K | 550.70K | 424.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.54M | 2.10M | 3.38M | 3.38M | 3.95M |
| Operating Income | -5.54M | -2.10M | -3.38M | -3.38M | -3.95M |
| Income Before Tax | -5.54M | -2.10M | -3.38M | -3.38M | -3.95M |
| Income Tax Expenses | 900.00 | 0.00 | -- | -- | 1.60K |
| Earnings from Continuing Operations | -5.54M | -2.10M | -3.38M | -3.38M | -3.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.54M | -2.10M | -3.38M | -3.38M | -3.95M |
| EBIT | -5.54M | -2.10M | -3.38M | -3.38M | -3.95M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.15 | -0.06 | -0.09 | -0.09 | -0.11 |
| Normalized Basic EPS | -0.10 | -0.04 | -0.06 | -0.06 | -0.07 |
| EPS Diluted | -0.15 | -0.06 | -0.09 | -0.09 | -0.11 |
| Normalized Diluted EPS | -0.10 | -0.04 | -0.06 | -0.06 | -0.07 |
| Average Basic Shares Outstanding | 36.17M | 36.19M | 36.21M | 36.21M | 36.38M |
| Average Diluted Shares Outstanding | 36.17M | 36.19M | 36.21M | 36.21M | 36.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |